"Getting to do cutting edge science with so many wonderful people and the latest technology makes Genentech DMPK special."
I joined Genentech in early 2008 just as Small Molecule Drug Discovery was building to critical mass and it’s been a pleasure working here ever since. I’ve had various responsibilities over the years in DMPK as well as in cross functional roles such as a Project Team Leader in discovery and development phases. I currently lead the in vitro and in silico predictive ADME group in DMPK where we support drug project teams spanning from Early Discovery to market. We deliver high quality, fit for purpose in vitro data focused on clearance, binding and DDI in addition to AI/ML models, ADME SAR tools and early PBPK modelling and simulation via home grown tools - all to enable project decision making and molecule progression. It’s a lot of fun doing excellent science with lovely people and we enjoy supporting the whole spectrum of discovery and development in DMPK.
Drug Metab Dispos 2018. 46:1285–1303. Cited in FDA 2020 DDI guidance.
I’m passionate about using in vitro and in silico ADME to enhance and enable Research and Development. We know patients are waiting for the new medicines our work helps project teams deliver. My personal research interests include DDI, IVIVE, PBPK and predictive ADME.